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1. Antibiotics
Pathogenic microorganisms can infect tissues of human by destroying cellular
functions. Microorganisms themselves or their toxins can damage host cells. Micro-
bial infections are treated with antimicrobials by either inhibiting the microbial
growth or killing the microorganism. Antibiotics are widely being used not only in
the treatment of acute and chronic infections, but also in the prophylactic treatment
[1]. Targets of antimicrobials are cell membrane, cell wall, protein synthesis, nucleic
acid synthesis, and biological metabolic compound synthesis (Figure 1) [2]. Over
usage of antibiotics, mutations in the genes, carrying resistance genes in chromo-
somes and plasmids, gaining resistance genes carried by transposons, insertion
sequences (IS) and conjugation from the same or other species of microorganisms
cause bacteria develop resistance to antimicrobials [3].
2. The action mechanisms of antibiotics and antibiotic resistance
2.1 Injury to cell membrane
Plasma membrane of microorganism that has selective permeability contributes
active transport to gain energy as ATP. Cytoplasmic content and gradient such as
micro and macromolecules and ions are controlled by active transportation via
integral transporter proteins. When selective membrane permeability is disrupted
by antimicrobials, ions are lost and cellular ion gradient is distorted, so, the organ-
ism undergoes cellular damage and death [4].
Plasma membranes of bacteria are constructed by fatty acids that can be syn-
thesized in cell or taken from environment as building blocks. Targets of antimi-
crobials are metabolic steps of fatty acid synthesis and membrane phospholipids.
Polymyxin B, that is a bactericidal antibiotic, has been used as one of very few drugs
in the treatment of Gram-negative bacteria such as Pseudomonas [2]. Polymyxin B
that has detergent-like peptides having lipophilic and hydrophilic groups disrupts
phosphatidylethanolamine of membrane. Valinomycin, that is an ionophore, dis-
rupts cellular membrane potential that contributes oxidative phosphorylation by
forming pores in cellular membrane. Daphtomycin that is widely used in blood-
stream, wound, and soft skin infections caused by β-lactam especially vancomycin-
resistant Staphylococcus aureus disrupts membrane potential by depolarization, that
means potassium ions are released from cytoplasm to extracellular matrix [4].
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Daptomycin, amphotericin B, colistin, imidazoles, and triazoles also act as inhibi-
tors of cell membrane [2, 4].
2.2 The effect of antibiotics against cell wall
2.2.1 Cell wall synthesis
Cell walls of microorganisms are constructed by peptidoglycan. Glycan polysac-
charide strands are linked by crosslink that bind polypeptides bound to N-acetyl
muromic acid (NAM) of each polysaccharide strands.
After bactoprenol, which is a membrane-bound acceptor, transfers UDP-NAM-
pentapeptide and UDP-NAG from cytoplasm to outer site of cell membrane,
transglycosylation, and transpeptidation reactions are catalyzed by penicillin-
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2.2.2 Degradation of structure and function of cell wall
Certain antibiotics such as β-lactam antibiotics react with PBPs having high
affinity to β-lactams by binding to PBPs as a substrate. These drugs are structural
analogs of acyl-D-alanyl-D-alanine that binds to active site of PBP as a substrate of
PBP during transpeptidation reaction. Transpeptidation reaction is blocked by these
antibiotics inactivating transpeptidase domain of PBPs. Microorganisms are killed
by these cell wall inhibitors that inhibit peptidoglycan biosynthesis [3].
2.2.3 β-lactamases and the mechanisms of β-lactam resistance
β-lactamase, that is an enzyme synthesized by many species of Gram-positive
and Gram-negative bacteria, inactivates β-lactams degrading amide bond of β-
lactam ring of β-lactam antibiotics [4] (bnmMRSA and MSSA). β-lactamases can be
mediated by either plasmids or chromosomes, whereas penicillinases of Staphylo-
coccus aureus are plasmid mediated, many Gram-negative bacteria are chromosom-
ally mediated. β-lactamases that are plasmid mediated have tendency to be
transferred between distinct species of bacteria. Chromosomally mediated β-
lactamases can be either produced constructively as in the species of Bacteroides and
Acinetobacter or induced as in the species of Enterobacter, Citrobacter, and Pseudo-
monas. Extended-spectrum β-lactamases (ESBLs) that are one class of β-lactamases
having distinct ability to hydrolyze β-lactam rings of cefotaxime, ceftazidime, and
aztreonam can be seen in a few species of Gram-negative bacteria such as Klebsiella
pneumoniae and Escherichia coli [4].
β-lactamase is synthesized by blaZ gene and regulated by blaI and blaRI located
in plasmid or transposon. When β-lactam is not used, by binding of BlaI synthesized
by blaI gene to promoter-operator region of blaI-blaRI operon, β-lactamase is not
transcriped by blaZ gene. But in the treatment with β-lactam antibiotics, active site
of BlaRI which is a signal transducer integral protein of β-lactam is blocked by β-
lactam. After this blockage of active site, intracellular zinc metalloprotease domain
of BlaRI releases BlaI bound to blaI-blaRI operator. By upregulation of blaZ gene, β-
lactamase enzyme is synthesized, so the microorganism develops resistance to β-
lactam used [3].
2.3 Inhibition of metabolic biological compounds synthesis
Biological metabolic reactions are catabolized by enzymes that are activated by
substrates. Synthesis of metabolic biological compounds can be inhibited by drugs
as a competitive inhibition manner. Drugs that are structural analogs of substrates
act as substrates for the enzymes used in metabolic reactions.
Para-aminobenzoic acid (PABA) is a substrate for folic acid synthesis that is a
coenzyme in the reactions of purines, pyrimidine, and amino acids synthesis [2].
Sulfanilamide and 3,4,5-trimethoxybenzylpyrimidine are the examples of drugs
inhibiting synthesis of metabolic biological compounds. Sulfonamides (Sulfa drugs)
have been used in many infections such as urinary tract infections. Sulfonamide is
widely used in combination with other compounds. Silver sulfadiazine, one of the
combined drugs, is used in burn infections [2].
Trimethoprim sulfamethoxazole (TMP-SMZ) is another combined drug used
widely because of its synergistic activity. Trimethoprim and sulfamethoxazole block
distinct steps of DNA and RNA precursor synthesis, and protein. Sulfamethoxazole
that is sulfonamides showing structurally analogy with PABA blocks the reaction
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synthesizing dihydrofolic acid (DHF) from PABA, whereas trimethoprim that is
sulfonamides showing structurally analogy with DHF blocks the reaction synthe-
sizing tetrahydrofolic acid (THF) from DHF (Figure 2) [2].
2.4 Inhibition of nucleic acid synthesis
Antibiotics can inhibit replication, transcription, and folate synthesis of micro-
organisms.
2.4.1 Blockage of replication
2.4.1.1 Replication of DNA
Deoxyribonucleotide precursors are synthesized for the polymerization of
deoxynucleotides. By kinase enzyme, deoxynucleoside triphosphates (dNTP: dGTP,
dCTP, and dATP) are synthesized from deoxynucleoside diphosphates (dNDP:
dGDP, dCDP and dADP) that are synthesized from ribonucleosides by ribonucleo-
tide reductase. But deoxythymidine triphosphate (dTTP) is synthesized by differ-
ent pathway. Deoxyuracil diphosphate (dUDP) that is synthesized from uracil
diphosphate (UDP) by ribonucleotide reductase is converted to deoxyuracil
monophosphate (dUMP). Thymidylate synthetase catalyzes a reaction that converts
dUMP methylated by tetrahydrofolate (THF) to dTMP. In this step,
tetrahydrofolate (THF) is synthesized from dihydrofolate (DHF) by dihydrofolate
reductase. Finally, dTTP is synthesized from dTMP by kinase (Figure 2).
DNA gyrase opens DNA strands for the polymerization of deoxynucleotides by
DNA polymerase according to the each circular template strand of chromosome [5].
2.4.1.2 Inhibition of replication and the mechanisms of resistance
Kinolons, such as nalidixic acid and ciprofloxacin that is used in the treatment of
infections caused by Pseudomonas spp., prevent the formation of replication fork by
inhibiting DNA gyrase, as a result of binding to gyrA subunit. Novobiocin and
coumermycin prevent the formation of replication fork by inhibiting DNA gyrase,
as a result of binding to gyrB subunit. When gyrA and gyrB genes of bacteria are
Figure 2.
The synthesis of deoxynucleoside triphosphate precursors (dNTP: dATP, dGTP, dCTP, and dTTP), and the
inhibition of tetrahydrofolate (THF) and dNTP synthesis by antibiotics.
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mutated, bacteria develop resistant against these antibiotics [5]. Norfloxacin,
gatifloxacin, gemifloxacin, and moxifloxacin are the other groups of
floroquinolones having broader spectrum of activity. Floroquinolones are nontoxic.
Ciprofloxacin, norfloxacin, gatifloxacin, and gemifloxacin are used to treat urinary
tract infection and pneumonia [2].
Synthesis of deoxynucleotide precursors that are used in the replication of
DNA can be blocked by trimethoprim, hydroxyurea, 5-fluorodeoxyuridine, and
5-fluorouracil.
Trimethoprim is an inhibitor of folate synthesis. Trimethoprim, that is a struc-
tural analog of DHF, prevents the synthesis of THF by inhibiting dihydrofolate
reductase. So, dTMP that is a precursor of deoxynucleotide polymer is not synthe-
sized. There are many mechanisms of trimethoprim resistance. If thyA gene of
microorganism undergoes to mutation that inactivates thymidylate sentetaz dTMP
and DHF are not synthesized, as a result of inability in the transfer of methyl group
from THF to dUMP. Due to dihydrofolate reductase is not synthesized in the
microorganism of which thyA gene is mutated, this microorganism is not inhibited
by trimethoprim. If the microorganism changes the binding site of the
dihydrofolate reductase, the trimethoprim cannot bind to dihydrofolate reductase.
So, bacteria develop resistance to trimethoprim. Another mechanism of trimetho-
prim resistance is carrying gene causing resistance to trimethoprim [5].
Hydroxyurea inhibits ribonucleotide reductase that catalyzes deoxynucleoside
diphosphate from ribonucleoside diphosphate (Figure 2). If microorganism of gene
coding ribonucleotide reductase is mutated, microorganism develops resistance to
hydroxyurea [5].
Precursor synthesis can be blocked by 5-fluorodeoxyuridine and 5-fluorouracil
with competitive inhibition. Monophosphate forms of 5-fluorodeoxyuridine and
5-fluorouracil are structural analogs of dUMP that is the substrate of thymidylate
synthase. They inhibit the synthesis of dTMP. If the microorganism of gene coding
thymidylate synthase is mutated, the microorganism develops resistance to
5-fluorodeoxyuridine and 5-fluorouracil [5].
Dideoxynucleotides that are used as drugs are similar with deoxynucleotide
precursors, except that the hydroxyl group is absent in their 30 carbon. Dideoxynu-
cleotides that mimic deoxynucleotide precursors corpore into DNA and then, stop
replication, due to it cannot be bound by the next deoxynucleotide.
Mitomycin C blocks replication by binding guanine bases that are located in both
template strands of DNA [5].
2.4.2 Blockage of transcription
2.4.2.1 Transcription
Genetic information is transcripted from DNA to RNA by RNA polymerase that
catalyzes a reaction, binds ribonucleotides with phosphodiester bond. RNA poly-
merase is constructed by 2α, 1β, 1β0, 1ω, and 1σ subunit. Transcription that is
initiated by σ subunit that binds to promoter elongates until it is terminated by
termination protein P (Rho) that is a RNA-DNA helicase releasing transcript from
template DNA by breaking hydrogen bonds produced between template DNA
and transcript [5].
2.4.2.2 Inhibition of transcription
Rifampin, that is a derivative of rifamycine family of antibiotics, blocks initia-
tion of transcription by binding to β subunit of RNA polymerase. Rifampin is
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used in the treatment of infections caused byMycobacterium tuberculosis,Mycobac-
terium leprae, and bacteria for which treatment is hard is not toxic to humans, due
to it does not inhibit eukaryotic RNA polymerase. Mutated gene that codes
RNA polymerase containing a distinct β subunit structure causes the microorganism
to resist against ripampin. Streptolydigin also blocks initiation of transcription by
binding with the β subunit of RNA polymerase. Bicyclomycin, the target of which is
termination protein P, prevents termination of transcription. Bleomycin produces
nicks on DNA. Bleomycin is not suitable in the usage for humans, because they are
not specific to bacteria and has high toxic effect against humans and animals;
whereas, it is used for the experiments of transcription. Azaserin blocks transcrip-
tion by inhibition of ribonucleoside triphosphate synthesis [5].
2.5 Inhibition of protein synthesis
2.5.1 Translation
Protein is translated from mRNA by tRNA in ribosome. Translation is initiated
by the binding of formylmethionine tRNA-aminoacyl-tRNA (fMet-tRNAf
Met),
translation initiation region (TIR) of mRNA and initiation factor 2 (IF-2) to P site
of 30S subunit of ribosome and the formation of 70S complex as a result of the
release of IF-2. Translation continues with the binding of a new aminoacyl tRNA to
A site, transferring the polypeptide from tRNA bond to P site to tRNA bond to A
site by peptidyl transferase, and translocating of polypeptidyl tRNA from A to P site
by elongation factor-G (EF-G), until translation is terminated by termination
protein P (Rho) [5].
2.5.2 Inhibitors mimicking tRNA
Puromycin that mimics aminoacyl tRNA enters into ribosome and is added to
polypeptide grown, but it is not translocated from A site to P site of ribosome.
Polypeptide containing puromycin at the carboxyl terminal is released from ribo-
some and translation is terminated. Puromycin is toxic to humans and animals, as it
inhibits translation of eukaryotes [5].
2.5.3 Inhibitors binding to 23S rRNA
2.5.3.1 Chloramphenicol
Chloramphenicol, that is a bacteriostatic agent and the inhibitor of 23S rRNA,
inhibits transcription by preventing peptidyl transferase reaction, as a result of
preventing the binding of aminoacyl tRNA to A site of ribosome. Due to its
ability enter into blood-brain barrier, chloramphenicol is used in the treatment
of many central nervous system infections such as bacterial meningitis. If the
gene of ribosomal protein is mutated or bacteria has enzyme inactivating
chloramphenicol, coded by cat gene of Tn9, bacteria resists to chloramphenicol.
The product of cat gene that acetylates chloramphenicol inactivates
chloramphenicol [5].
2.5.3.2 Erythromycin
Erythromycin, that belongs to macrolide class of antibiotics, inhibits
translation by binding to 23S rRNA. As a result of the blockage of E site, that is the
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exit site for peptidyl-tRNA by erythromycin, premature polypeptide is released
in translocation step. Macrolites, such as erythromycin, clarithromycin,
azithromycin, and roxithromycin, are used in the treatment of Gram-positive and
Gram-negative bacteria such as Legionella,Mycoplasm, and Rickettsia, due to use-
fulness of antibiotics. Mutational changes in 23S rRNA and efflux pumps, and
conformational changes of 23S RNA that is caused by methylation of adenine
localized in 23S rRNA by Erm methylase cause bacteria to resist against
erythromycin [5].
2.5.3.3 Thiostrepton
Thiostrepton and other thiopeptide antibiotics block translation by binding
to 23S RNA in the peptidyl transferase reaction and preventing the binding of EF-G
that is a translocase translocating polypeptidyl tRNA from A to P site. Thiostrepton
is used against Gram-positive bacteria. But the usage of thiostrepton is limited to
veterinary and agriculture [5].
2.5.4 Inhibitors binding to A site of aminoacyl tRNA
2.5.4.1 Tetracyclin
Tetracyclin causes futile cycle to release aminoacyl tRNA from A site of ribo-
some by binding of release factors mimicking aminoacyl tRNA to A site. Tetracyclin
is a broad spectrum antibiotic used to treat infections caused by Gram-positive
and Gram-negative bacteria. tetM gene transferred from conjugative transposon
Tn916 codes not only an enzyme that causes resistance by methylating certain bases
of 16S rRNA, but also membrane proteins that pump tetracyclin to out of the cell,
consequently resistance is developed. Ribosome protector proteins coded by tetO
and tetQ gene bind to A site of ribosome by mimicking EF-G, consequently
tetracyclin is released from A site [5].
2.5.5 Inhibitors of translocation
2.5.5.1 Aminoglycosides
Aminoglycosides that contain kanamycin, neomycin, gentamycin, streptomy-
cin, amikacin, and tobramycin effect translocation by binding to A site.
Aminoglycosides that have broad spectrum of activity cause false reading of
mRNA and translation errors. Mutants that are resistant to aminoglycosides are
seen rare. Aminoglycoside resistance is caused by the genes that inactivate
aminoglycosides by phosphorylation, acetylation, and adenylation of them. neo
gene that phosphorylates kanamycin and neomycin cause resistance of
Gram-negative bacteria against kanamycin and neomycin [5].
2.5.5.2 Fusidic acid
Fusidic acid inhibits turnover of EF-G by preventing the release of EF-G from
ribosome. Mutations that are occurred in fusA gene of E. coli cause resistance against
fusidic acid. Certain acetyltransferases causing resistance against chloramphenicole
can inhibit fusidic acid by binding to fusidic acid [5].
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